Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$406 Mln
P/E Ratio
--
P/B Ratio
1.21
Industry P/E
--
Debt to Equity
0.06
ROE
-0.43 %
ROCE
-41.57 %
Div. Yield
0 %
Book Value
6.01
EPS
-2.34
CFO
$-243.45 Mln
EBITDA
$-349.74 Mln
Net Profit
$-475.05 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
| -10.20 | 7.04 | -23.28 | -60.53 | -18.83 | -5.13 | -16.46 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
| -67.46 | 560.29 | -71.41 | 86.02 | -57.55 | -17.99 | 74.47 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 62.11 | 11,346.08 | 26.54 | 8.05 | |
| 69.19 | 6,636.14 | 51.14 | 23.56 | |
| 58.02 | 11,265.03 | 378.67 | 0.76 | |
| 7.83 | 9,036.23 | -- | -3.24 |
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained... intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Address: 480 Pleasant Street, Watertown, MA, United States, 02472 Read more
President, CEO & Director
Dr. Jay S. Duker M.D.
President, CEO & Director
Dr. Jay S. Duker M.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Eyepoint Pharmaceuticals Inc (EYPT) stood at $ 418 Mln as on 31-Dec-24
The share price of Eyepoint Pharmaceuticals Inc (EYPT) is $6.69 (NASDAQ) as of 23-Apr-2025 14:40 EDT. Eyepoint Pharmaceuticals Inc (EYPT) has given a return of -18.83% in the last 3 years.
Eyepoint Pharmaceuticals Inc (EYPT) has a market capitalisation of $ 406 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Eyepoint Pharmaceuticals Inc (EYPT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Eyepoint Pharmaceuticals Inc (EYPT) and enter the required number of quantities and click on buy to purchase the shares of Eyepoint Pharmaceuticals Inc (EYPT).
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Address: 480 Pleasant Street, Watertown, MA, United States, 02472
The CEO & director of Dr. Jay S. Duker M.D.. is Eyepoint Pharmaceuticals Inc (EYPT), and CFO & Sr. VP is Dr. Jay S. Duker M.D..
There is no promoter pledging in Eyepoint Pharmaceuticals Inc (EYPT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Eyepoint Pharmaceuticals Inc (EYPT) | Ratios |
|---|---|
|
Return on equity(%)
|
-43.42
|
|
Operating margin(%)
|
-302.19
|
|
Net Margin(%)
|
-302.43
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Eyepoint Pharmaceuticals Inc (EYPT) was $0 Mln.
$0.19
(
